The Misuse of Drugs Act 1971 (Amendment) Order 2021
| Jurisdiction | UK Non-devolved |
| Citation | SI 2021/868 |
| Year | 2021 |
2021 No. 868
Dangerous Drugs
The Misuse of Drugs Act 1971 (Amendment) Order 2021
Made 21th July 2021
Coming into force 18th August 2021
At the Court at Windsor Castle, the 21st day of July 2021
Present,
The Queen’s Most Excellent Majesty in Council
In accordance with section 2(5) of the Misuse of Drugs Act 19711, a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.
Accordingly, Her Majesty, in exercise of the powers conferred on Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:
Citation, commencement and extent
1.—(1) This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2021 and comes into force twenty-eight days after the day on which it is made.
(2) This Order extends to England and Wales, Scotland and Northern Ireland.
Amendment to the Misuse of Drugs Act 1971
2.—(1) The following amendments are made to Part 3 of Schedule 2 to the Misuse of Drugs Act 1971 (which specifies the drugs which are subject to control under that Act as Class C drugs).
(2) In paragraph 1(a)2—
(a)
(a) after “Fenproporex.” insert “Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine).”;
(b)
(b) after “Flunitrazepam.” insert “Flunitrazolam (6-(2-fluorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine).”;
(c)
(c) after “Nordazepam.” insert “Norfludiazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one).”.
Ceri King
Deputy Clerk of the Privy Council
EXPLANATORY NOTE
(This note is not part of the Order)
This Order brings certain drugs under the control of the Misuse of Drugs Act 1971 (c. 38). Article 2(2) of this Order brings three benzodiazepines, being the compounds known as flualprazolam, flunitrazolam and norfludiazepam, under control as Class C drugs under that Act.
A full impact assessment has not been produced for this instrument as no, or no significant, impact on the private, voluntary or public sectors is foreseen.
To continue reading
Request your trial